|
Post by careful2invest on Mar 6, 2017 19:06:55 GMT -5
The Sanofi money deal wasn't a deal.... they pretty much said, "Here is some pocket change it should put you right back where you were, financially, before we started our partnership." They should have tried for triple that, but again difficult to accomplish when you are arguing from a "position of strength." I don't know which one is funnier: "abundance of riches" or "position of strength?" Just for the record, the quote was an "embarrassment of riches" I cannot help but to replay those quotes over and over... Hard to take! Or how about this one from so many that tried so hard to find the positive all along while MNKD blundered along... We should thank MNKD fo yet another "buying opportunity" Is this just another great "buying opportunity"? I personally cannot pull that trigger! I do not think that we are totally dead yet, but the silence from MNKD is deafening! If they truly have that Ace in the hole, I'd be extremely surprised! BUT I WOULD WELCOME IT MATT!! As would the others on this mb and elsewhere that believed you and believed in you! To date, you have not only let us down, you have mislead us as well! But Remember folks, It's not over until it's over ! I believe that the only thing to help us out of this mess is 🙏!
|
|
|
Post by careful2invest on Mar 6, 2017 14:42:08 GMT -5
Very sad to see MNKD wither away to this... I had so much hope for Afrezza. My investment has gone to shit & there appears to be no light at the end of the tunnel! Cant be! Our CEO, CFO, told us that they they were sitting on an "embarrassment of riches" that there would be an "epic turnaround" and just recently, the "reverse split is from a position of strength" Surly he would not lie to his investors... Maybe he got the order confused in his wording... Maybe he meant that if one once had plenty of "riches", they would soon be "embarrassed" about their "epic turnaround" in their tax bracket and that their once "position of" financial "strength" is a thing of the past after investing in MNKD!! The company that he burried! F'ing frustrated at their lack of business prowess!! Amateurs !! And it cost me a nut!!
|
|
|
Post by careful2invest on Mar 6, 2017 13:40:52 GMT -5
It will be a failure if we go under $1 in 10 days from split, no? I didn't even think about that until someone mentioned it in another thread. Yes if that occurs, the rs would be a huge failure but how can you blame management for the sell off at that point The blame on MNKD Management goes way back! You can blame management for being totally silent and not being proactive in promoting or defending AFREZZA over the last two plus years!! Thats how!
|
|
|
Post by careful2invest on Mar 4, 2017 20:15:03 GMT -5
Back to those six words again... It just does not make sense!Quote: If I were Matt I would have stood outside the Trump elevator after 11/8 and tried to get a meeting. reply: I can not figure out how this would benefit Trump. Although he looks like his blood glucose levels could be running high and he is 70.
Hell, Crazy Kanye West got a meeting with Trump! If Trump were to blow the whistle on the Big Pharma, All of AMERICA would love him! Even the Liberals and the Democrats! Although he would lose the support of the Billionaires associated with Big Pharma! But look at the lives that he would help and even save! Who would not like that stamp of achievements on their Resume? Not with Washington, but for mankind!
|
|
|
Post by careful2invest on Mar 4, 2017 19:58:50 GMT -5
Hell yes, it's WAAY past time for someone at MNKD to get tee'd off and go on offense. Or get someone on team Trump in the game - He's no fan of the FDA. This sh-t show has been going on long enough. And we are the ones eating sh-t. I guess Matt's definition of "turnaround" is reverse as in reverse split - yeah - that's epic alrighty. I'll have an epic rant/therapy thread at some point over the next day or two - Surplus has this management team nailed. IMO - Mike C is the ONLY positive and - wait for it....we still haven't cracked 300 scripts. AWESOME!!!! I can't figure Mannkind out. In the situation MNKD is in, you would expect urgency. If I were Matt I would have stood outside the Trump elevator after 11/8 and tried to get a meeting. Give an envelope to everyone going up to the 23rd floor and ask for a meeting. There are so many things they could discuss; price fixing; doctor fixing; doing a deal with the VA; working with Ben Carson to setup inner city clinics - Project Power would die for a deal; and more. He could even bring Bernie Sanders with him and Elijah Cimmings I have to believe Matt is either delusional or he really has some big deal and the famous embarrassment of riches will soon happen. I sure hope its the latter but at this point it looks more like the former. How about these sales guys. Can they sell something? How about 1 new script per endo per week with 80% retention? Is that too much to ask, 2 scripts might be asking too much. Assuming 2000 endo's in no time they would hit that magic 12,000 scripts per week. 40 sales guys and 200 scripts in a week. My head is about to explode. The worst product in the world should be doing that not the best. Its all so strange. Back to those six words again... It just does not make sense!
|
|
|
Post by careful2invest on Mar 4, 2017 14:11:03 GMT -5
Perfect time for MNKD to differentiate themselves even more in the public eye and media in general by showing that not only were they (MNKD) not a part of it. MNKD can announce that they have lowered the price of AFREZZA. In doing so, MNKD can appear to be the hero humanitarians that not only charge less, but offer an alternative that can actually lower a users A1C at the same time, and oh yea, it's also inhaleable! If MNKD does not try to monopolize on this event, they are truly inept and I made a $200,000.00 plus dollar mistake in my investment. If this does not pan out, I'm going to have to change my screen name. Because clearly, I was not careful enough 2 invest! I feel that if they drastically lower their price in the midst of this that it would be *I can't think of a word I am feeling about it, but almost would be like saying it is already way too high and also they would be setting themselves up for a trap. If they lower it and then need to raise it legitimately, they potentially would face scrutiny. I don't think they need to lower the price. I do think that there could be an opportunity to draw positive attention however, but in what way and what form I have no idea. I respect your opinion, and thank you for posting this find, but in response to your post, The fact is that AFREZZA is basically not selling. When your product or service is not selling, from a marketing perspective, you must identify the problems... In part, it was insurance and spirometry in the beginning, MNKD has addressed those issues. What is it now? Partly still due to Label, lack of exposure and advertisement, Doctors reluctance to try it, (Docs receiving too much money from BP?) etc...etc But when current methods of sales are not working, one must think of an angle to gain that edge to sell your product. The ability to lower your price is probably the most effective, although I am not minimizing the importance of the aforementioned. Nowhere did I say a "drastic" reduction, simply just sell lower than your competition. Once you gain market acceptance, gradually raise your price to a point of fair, yet decent sustainable profit margins. If Afrezza works as good as reported by so many, with longterm benefits due to "time in range" etc, most patients would be willing to pay a little more for a better quality of life and even an extension of life! Once proven, Insurance companies would probably soon follow. I do not get MNKD's MO! And all the while, the pps gets slaughtered!!
|
|
|
Post by careful2invest on Mar 4, 2017 13:03:07 GMT -5
Didn't post the entire content, that is 169 pages. I just posted the section I found most interesting. On purpose. Perfect time for MNKD to differentiate themselves even more in the public eye and media in general by showing that not only were they (MNKD) not a part of it. MNKD can announce that they have lowered the price of AFREZZA. In doing so, MNKD can appear to be the hero humanitarians that not only charge less, but offer an alternative that can actually lower a users A1C at the same time, and oh yea, it's also inhaleable! If MNKD does not try to monopolize on this event, they are truly inept and I made a $200,000.00 plus dollar mistake in my investment. If this does not pan out, I'm going to have to change my screen name. Because clearly, I was not careful enough 2 invest!
|
|
|
Post by careful2invest on Mar 4, 2017 11:22:49 GMT -5
That's a stretch. However, even if factual you might want to recall that it was Sanofi-Aventis who was given 100% of the authority to set Afrezza's price. At the time, we all squawked about them establishing pricing at a premium to RAA insulin. In retrospect, it seems obvious that they set the price of Afrezza knowing in advance that the big insulin brands were about to raise the price of their pens. My main point, though, is that MannKind did not set the price for Afrezza. They simply chose not to lower it. "They simply chose not to lower it" Yet, Another mistake by MNKD!The oportunity to get more exposure when the spotlight is on Insulin pricing (Bernie Sanders etc.) is now! MNKD can come out of the gate with a new lower priced option for Diabetes, that can actually lower a persons A1C and save them money and it's inhaled! It's called AFREZZA! Individual news stations would pick up the story, and word would get out about AFREZZA ! MNKD could look like the humanitarian hero to come to the rescue of Diabetics that cannot afford their insulin at MNKD's competitors prices. Maybe have a few patient testimonials infused in the story. If MNKD's "hands are tied" (so tired of hearing that) for whatever reason, There are ways to get this done! I'm sure that we could find a few enthusiastic users of AFREZZA that would be willing to participate. Something needs to happen before it is too late! Which I hope it's not too late already!
|
|
|
Post by careful2invest on Mar 3, 2017 17:41:13 GMT -5
I agree Dreamboat, and hopefully they can get exposure and sales where they need to sooner than later. And I realize the bs of "from a position of strength" But put it together with "Embarrassment of riches" and "Epic turnaround" and comments like those are getting old, real old. The deeper problem I think is that Matt actually thinks they're coming from a position of strength. Added with all of his past statements, correlated to their actions, it's clear to me that they believe these things to be true. They've showed up stunned to more than one conference in the past in disbelief of their situation. If that is the case, we desperately need a more experienced skipper at the helm! Before it is absolutely too late. Which unfortunately, it may be already! I am a reasonably long term long (7 years) but I am losing faith in this company! As well a losing six figures in this company that could have been doing something worth while elsewhere.
|
|
|
Post by careful2invest on Mar 3, 2017 17:36:20 GMT -5
Short sellers aren't what's killing the share price. Poor management and poor sales are. 1/12/2016 Short Interest 130,253,946 Share price: $0.96 2/15/2017 Short Interest 101,613,853 Share Price: $0.53 30M fewer short shares = 30M shares purchased to cover, yet the share price gets cut in half. Look to management, not to a scapegoat. if anything, short sellers supported the share price by taking profits. In the meantime, MNKD issued millions of warrants that short sellers use to protect their position. While we're at it, although I have never shorted the stock of any company (my registered investment account does not allow it, and I'm just as happy about that), the short investment thesis: IS NOT: "I hate diabetics so I'll bankrupt a biotech company" (Shorting doesn't bankrupt companies. Running out of money does) It IS: "I think the share price will be lower in the future" OR "I think shorting this company will be a hedge to my investment in another company" That said, I just looked at the SP. $1.87. Makes me want to cry. A pile-on of selling (shorting or longs lightening positions) could indeed take this under $1.00 in the next 10 days. The BOD should be ashamed of themselves for not selecting the 10:1. It would have given a much larger margin of safety. I agree, but of course I subscribe to the age old adage that if you are going to sale something that you want people to buy, someone has to talk about it. When people talk about it, people buy it and "boom" there goes your sales. You run out of money when you hire and send a bunch of sales reps to go to doctor's office and talk about a drug that no ones heard of. ADVERTISE it on television, people will go to their doctors and inquire and request it, and the sales representatives will be able to do their jobs. I am not an expert at this, but I think I'm on to something here. I'd say that you are definitely onto something, to put it mildly. It is such a blatantly obvious concept to make your potential customer aware of the goods that you want to market, (that is only if you intend to sell as much of your product as possible) that it almost seems intentional that MNKD management wants to bury this company as much as BP wants it gone! A reverse split, with no announcement of something positive to reduce or eliminate further dillution?? What are they (MNKD) thinking? With each decision, there is another missed opportunity, another blunder. Seven plus years of disappointment. I have witnessed it even prior to FDA approval! Sad thing is, it's not even worth it to sell the shares that I have. Unfortunately, I just have to ride it out. Hopefully they can turn it around! It just does not make sense!
|
|
|
Post by careful2invest on Mar 3, 2017 17:13:58 GMT -5
They could still start advertising in a low cost, well put together, efficient and effective way until they get the label change and then build from there. The biggest problem is...No one has ever heard of AFREZZA! Yet MNKD does a reverse split "from a position of strength" no less, and we find ourselves down another 12 percent. It just does not add up! The "from strength" was simply BS. Wish they hadn't used that phrase. So don't try to add that up to anything. The price action since announcement of RS vote through today adds up quite well with what normally happens with companies forced to do RS. I'm just hoping they can do some targeted advertising... online targeted at PWD and on TV targeted at specific regions with the highest payer coverage and where extra effort has gone to educate doctors. If they could show a strong turn around in one geographic region I think that could be the foundation for a raising capital. At least it would be better than raising capital the way things stand now... if that would even be possible. I agree Dreamboat, and hopefully they can get exposure and sales where they need to sooner than later. And I realize the bs of "from a position of strength" But put it together with "Embarrassment of riches" and "Epic turnaround" and comments like those are getting old, real old.
|
|
|
Afrezza
Mar 3, 2017 16:50:31 GMT -5
Post by careful2invest on Mar 3, 2017 16:50:31 GMT -5
Peppy, its nice to see good investigative thinking but this really again points to management's incompetence (again). And what I see is an incredible amount of effort (including education/promotion) by some shareholders trying to do what management should be doing effectively . It shouldnt be up to the patients or even the doctors to figure this out (and certainly not the shareholders). This is MNKD's responsibility. With a disruptive and revolutionary product you need clear knowledge regarding titration and dosing including step size and timing which all affect retention. How can MNKD spend all this time, effort and funds to educate the endos and still not know what they are doing. Who is going to educate the educator? Forget about the share price and the financial issues ;were talking about the basic properties of the product they cant even instruct on. This should have been figured out a very long time ago. It's appalling. It's no wonder MNKD is where it is. ' But MannKind can't tell the endos anything beyond what the label (currently) says. Why is that so hard to understand? When we get a label change then MannKind can more correctly instruct the docs. Until then the company's hands are tied. They could still start advertising in a low cost, well put together, efficient and effective way until they get the label change and then build from there. The biggest problem is...No one has ever heard of AFREZZA! Yet MNKD does a reverse split "from a position of strength" no less, and we find ourselves down another 12 percent. It just does not add up!
|
|
|
Post by careful2invest on Feb 27, 2017 22:51:54 GMT -5
The answer is in the hands of the new full-time 90+ sales force that just started and the upcoming TV commercials. If they cannot get things going, it's game over!! Btw, What is the release date of the first commercial?
|
|
|
Post by careful2invest on Feb 19, 2017 15:30:34 GMT -5
Wow. Afrezza has a steep uphill battle. $$$$$ is the great motivator in our health care system. My questions to Mango: 1. Have you shared this information with MNKD management so there is NO DOUBT that they are aware? 2. If so, what was their response and action plan to combat this "recommendation" (publication) to the practitioners? I appreciate all the informative information you post. Too bad a investigative news show, like 60 Minutes, can't expose how $$$$$ is influencing our medical care givers. You would think they would jump on a story like this, especially since drug pricing has been in news lately. 1. Have you shared this information with MNKD management so there is NO DOUBT that they are aware?No. I honestly do not know how to convey all this information in a precise and condensed way, and for it to be informative and slap the point across that an executive would take the time to read and understand. I hope someone else can take the task of doing so. If not, someone can just tweet Mike to read the thread. 2. If so, what was their response and action plan to combat this "recommendation" (publication) to the practitioners?Who knows if MannKind will even share the same views. Mango, IMHO, Convey this information just as you did on this mb! Your perspective, (backed by proof) is very convincing! However, I honestly hope that MNKD is fully aware of this information, because if not, they are alarmingly inept! For MNKD not to be involved (at any capacity)in a seminar called "2017 Endo Concensus on T2D" alarms the crap out of me! Were they not permitted? That would be the only acceptable reason for MNKD not being there with bells on! Or with at least some spokesperson or group! It has been odd to all (or most) of us that MNKD has done little to no advertising promotion of AFREZZA, agreed? For MNKD not to be at a worldwide annual convention that is covering the treatments of Diabetes shows that making excuses for MNKD is over. At least from my perspective! They have missed opportunity after missed opportunity to spread the word about AFREZZA! It's almost as if they do not want to! It just does not make sense!
|
|
|
Post by careful2invest on Feb 19, 2017 14:57:39 GMT -5
Mango, you are assuming bad intentions, you claim they mentioned inhaled insulin as an afterthought, and you claim to know what the authors were thinking. Probably no one else here has read or has access to the actual article. I'm not quite sure what your intentions are. I do not claim to be able to read anyones mind, but if AFREZZA actually works as well as the many patients that are using it claim, wouldn't one tend to believe that people in the healing industry would be embracing it. AFREZZA mimics a healthy human pancreas, only monomer insulin, Lowering AIC, longer time in range, no needles, Diabetics can eat whatever they want (within reason) etc... It seem clear, and this is not news, Phamaceutical companies (in general) are not in the healing business. They are into the business of selling their product! Unfortunately for us, AFREZZA is not their product and it appears, (and is reinforced by mangos post) that the docs at this seminar (that have the power to move the needle) already have long ties to current producers of the outdated treatments of Diabetes strong enough to shrug and even shunn the replacement for the best treatment of Diabetes that is AFREZZA! We have a huge challenge ahead! MNKD needs to find someone infuential enough to break down this nearly impenetrable wall! Can the union with JDRF be enough? IDK?
|
|